Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a ...

Key Takeaways An already-approved MS drug can help people with the progressive form of the diseaseOcrelizumab delayed ...

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Secondary progressive multiple sclerosis (SPMS) can develop after relapsing-remitting multiple sclerosis (RRMS). It causes steady neurological decline, either with or without relapses. Switching from ...

If you’ve been recently diagnosed with SPMS, you may wonder how the transition between RRMS and SPMS will affect your MS treatment options and lifestyle. Most people with MS are initially diagnosed ...

Promising phase 3 trial results from French researchers indicate that the first-in-class oral TKI masitinib may provide a new treatment option for patients with primary progressive multiple sclerosis ...

Samantha Salvaggio learned she had relapsing-remitting multiple sclerosis (RRMS) in 2005, when she was a 19-year-old sophomore at Ohio State University. Over the next 16 years, she averaged one ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...